pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,997 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1174Endpoints892BioPharma Dive343BioSpace307Fierce Biotech290onclive165raps104globenewswire health73
therapy area
allOncology7598Rare Disease1873Cardiology1741Immunology1478Hematology1321Vaccines1197Pulmonology
  • Experts discuss emerging therapies shaping the future of relapsed and refractory multiple myeloma
    In a recent opinion segment, Dr. Ajay Nooka and Dr. Noopur Raje explore how new treatments and ongoing trials are influencing the landscape for patients with relapsed and refractory multiple myelom…
    onclive · 3mo agoNeutral↗ source
  • Experts discuss emerging MET-driven resistance data shaping second-line therapy for EGFR-mutated lung cancer
    In a recent video segment, Dr. Jacob Sands sits down with Dr. Heather Wakelee to talk about the impact of new findings on MET-driven resistance in EGFR‑mutated non‑small cell lung cancer. The conv…
    onclive · 3mo agoNeutral↗ source
← prev
page 69 of 80
next →
fda recalls70
fda medwatch60
fda press38
1185
Psychiatry & CNS866
Ophthalmology495
Pain480
Endocrinology & Metabolism474
Infectious Disease444
Sequencing antibody-drug conjugates adds complexity to recurrent endometrial cancer treatment
Therapy sequencing for recurrent endometrial cancer is becoming increasingly complex as immunotherapy moves earlier in the treatment pathway and antibody-drug conjugates (ADCs) gain traction. Expe…
onclive · 3mo agoNeutral↗ source
  • Experts highlight need for broader monitoring in polycythemia vera as patient shows disease progression despite controlled hematocrit
    A 68-year‑old woman with a six‑year history of polycythemia vera (PV) and prior deep‑vein thrombosis has kept her hematocrit below 45% on hydroxyurea, indicating good control of that metric. Desp…
    onclive · 3mo agoNeutral↗ source
  • AUA and SUO Issue 2026 Update to Advanced Prostate Cancer Guideline
    The American Urological Association (AUA) and the Society of Urologic Oncology (SUO) have released an amendment to their Advanced Prostate Cancer Guideline for 2026. The update revises recommendat…
    onclive · 3mo agoNeutral↗ source
  • Delayed and re-emergent immune-related adverse events can persist years after melanoma checkpoint therapy, says expert
    Dr. Michael A. Postow, chief of the Melanoma Service at Memorial Sloan Kettering Cancer Center, explained that immune checkpoint inhibitors (ICIs) for melanoma have a distinct toxicity profile comp…
    onclive · 3mo agoNeutral↗ source
  • GU oncology experts preview top abstracts slated for ASCO 2026
    The 2026 ASCO Annual Meeting will run from May 29 to June 2 in Chicago, featuring a dedicated genitourinary (GU) oncology program. Leading clinicians were asked what upcoming abstracts they conside…
    onclive · 3mo agoNeutral↗ source
  • Experts discuss emerging role of TROP2-directed ADCs in EGFR-mutated lung cancer
    The segment, part of a series on EGFR‑mutated non‑small cell lung cancer, featured Dr. Jacob Sands together with Drs. Heather Wakelee and Alissa Cooper. They explained that TROP2‑directed antibody…
    onclive · 3mo agoNeutral↗ source
  • Dr. Postow stresses need for long-term multidisciplinary monitoring after melanoma immunotherapy
    Dr. Michael Postow, chief of the Melanoma Service at Memorial Sloan Kettering Cancer Center, emphasizes the importance of long-term multidisciplinary monitoring for patients who have completed immu…
    onclive · 3mo agoNeutral↗ source
  • Experts discuss treatment sequencing after progression in multiple myeloma
    In a recent video segment, Dr. Ajay K. Nooka, Dr. Noopur S. Raje and Dr. Surbhi Sidana lead a discussion on how to approach treatment sequencing for patients whose multiple myeloma has progressed.…
    onclive · 3mo agoNeutral↗ source
  • Journalist reflects on challenges of reporting healthcare AI after fellowship
    The author participated in a journalism fellowship that focused on health technology reporting. The experience underscored the importance of continuously examining the incentives that drive AI pro…
    Endpoints · 3mo agoNeutral↗ source
  • FDA approves brexu-cel CAR-T therapy for relapsed/refractory mantle cell lymphoma, highlighting safety considerations
    The U.S. Food and Drug Administration has granted approval to brexu-cel, a CAR T-cell therapy, for patients with relapsed or refractory mantle cell lymphoma (MCL). This is the first CAR T indicatio…
    onclive · 4mo agoApprovalPositive↗ source
  • CSL shares plunge to nine-year low after cutting revenue forecast and announcing $5 billion impairment
    CSL's shares fell to their lowest level since early 2017 after the company reduced its full‑year revenue guidance by roughly four percent. The guidance cut signals slower sales growth than previous…
    Endpoints · 4mo agoEarningsNegative↗ source
  • Rezdiffra Beats Wall Street Forecasts as MASH Market Expands
    Rezdiffra, a drug candidate targeting metabolic dysfunction‑associated steatohepatitis (MASH), is outperforming analysts' expectations according to recent commentary. The optimism comes as the mar…
    Endpoints · 4mo agoPositive↗ source
  • Inhibrx reports 44% response rate when paired with Keytruda in head-and-neck cancer Phase 2 trial
    Inhibrx Biosciences said its experimental agent INBRX-106 boosted the activity of Merck's Keytruda in a Phase 2 study of a head-and-neck cancer. The combination achieved a 44% overall response rate…
    BioPharma Dive · 4mo agoPositive readoutPositive↗ source
  • Dr. Silbermann highlights trial design priorities for multiple myeloma, from supportive care to diverse enrollment
    Dr. Rebecca Silbermann, an associate professor at Oregon Health & Science University, outlined key considerations for designing multiple myeloma clinical trials. She stressed the importance of alig…
    onclive · 4mo agoNeutral↗ source
  • Zanubrutinib shows longer overall survival than ibrutinib in real-world relapsed/refractory mantle cell lymphoma
    A retrospective real‑world analysis examined outcomes of covalent BTK inhibitors in patients with relapsed or refractory mantle cell lymphoma who received treatment in the second or third line. Th…
    onclive · 4mo agoPositive readoutPositive↗ source
  • GSK partners with Sino Biopharma to expand access to hepatitis B drug bepirovirsen in China
    GSK announced a marketing agreement with Sino Biopharmaceutical to distribute its experimental hepatitis B therapy bepirovirsen in China. Sino's subsidiary will purchase a supply of the drug and u…
    BioPharma Dive · 4mo agoDealPositive↗ source
  • INBRX-106 plus pembrolizumab shows higher response rate than pembrolizumab alone in first-line PD-L1-positive head-and-neck cancer
    The HexAgon-HN trial evaluated the OX40 agonist INBRX-106 combined with pembrolizumab in patients with treatment-naive, PD-L1‑positive metastatic or unresectable head‑and‑neck squamous cell carcino…
    onclive · 4mo agoPositive readoutPositive↗ source
  • Daiichi Sankyo targets $15 billion in oncology sales by 2030 as it expands ADC franchise
    Daiichi Sankyo released a new five‑year business plan that sets a goal of nearly $15 billion in oncology revenue by 2030. The target is part of a broader ambition to push total company sales past 3…
    Endpoints · 4mo agoNeutral↗ source
  • Inhibrx reports combo of Keytruda and INBRX-106 reduces tumors more than Keytruda alone in metastatic head cancer
    San Diego biotech Inhibrx says its experimental drug INBRX-106, when added to Merck's immunotherapy Keytruda, led to a higher rate of tumor shrinkage than Keytruda by itself. The observation comes…
    Endpoints · 4mo agoPositive readoutPositive↗ source
  • Braveheart Bio's Hengrui-licensed cardiac therapy shows positive mid-stage trial results
    Braveheart Bio announced that its heart muscle therapy, licensed from Jiangsu Hengrui Pharmaceuticals, has achieved a positive outcome in a Phase 2 trial. The mid-stage study met its primary endpo…
    Endpoints · 4mo agoPositive readoutPositive↗ source
  • Biotech layoffs slow as companies like BioNTech cut nearly 1,900 jobs amid market pressures
    The biotech sector has seen more than 40 layoff announcements through the end of April 2026, a decline from the over 50 rounds reported in the final months of 2025. Analysts had expected the pace t…
    BioPharma Dive · 4mo agoLayoffsNegative↗ source
  • ctDNA testing shows promise for renal cell carcinoma and germ cell tumors despite current limitations
    Experts discussed how circulating tumor DNA (ctDNA) monitoring, long used in bladder cancer, is being explored for renal cell carcinoma (RCC) and germ cell tumors. In RCC, low tumor shedding has l…
    onclive · 4mo agoNeutral↗ source
  • ctDNA monitoring guides immunotherapy decisions in metastatic urothelial cancer
    Experts discussed how circulating tumor DNA (ctDNA) testing is being used to follow patients with metastatic urothelial carcinoma and to help shape immunotherapy choices. They noted that a rapid d…
    onclive · 4mo agoPositive↗ source